Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

A Pair of Gene Splice Isoforms Has Opposite Effects on Cancer Development

By BiotechDaily International staff writers
Posted on 21 Apr 2014
Two distinct splice isoforms of the MAP kinase interacting serine/threonine kinase 2 (MKNK2) gene have dramatically different roles in cancer development and growth.

It is known that the protein products of MKNK2 phosphorylate the eukaryotic initiation factor 4E (eIF4E), thus playing important roles in the initiation of mRNA translation, oncogenic transformation, and malignant cell proliferation. However, it has come to light that MKNK2 is alternatively spliced with the two splicing isoforms having different last exons: Mnk2a, which contains a MAPK-binding domain, and Mnk2b, which lacks it.

Investigators at the Hebrew University of Jerusalem (Israel) reported in the April 10, 2014, online edition of the journal Cell Reports that the Mnk2a isoform was a tumor suppressor that was downregulated in human cancers. This isoform interacted with, phosphorylated, and activated p38-MAPK, leading to activation of its target genes and to p38alpha-mediated cell death. Thus, Mnk2a downregulation by alternative splicing was a tumor suppressor mechanism that was lost in some breast, lung, and colon tumors.

On the other hand, the Mnk2b isoform was found to be pro-oncogenic and did not activate p38-MAPK, while still enhancing eIF4E phosphorylation.

These results suggested that Mnk2 alternative splicing served as a switch in several cancers to downregulate a tumor suppressor isoform (Mnk2a) that activates the p38-MAPK stress pathway and to induce an isoform (Mnk2b) that does not activate this pathway and is pro-oncogenic.

"The mechanism we discovered explains how cancer cells eliminate the anticancer form of Mnk2 without changing their DNA, and how they become resistant to anticancer treatments—a problem which exists for almost every cancer treatment today," said senior author Dr. Rotem Karni, senior lecturer of biochemistry and molecular biology at the Hebrew University of Jerusalem.

Related Links:

Hebrew University of Jerusalem 




Channels

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.